Azurity Pharmaceuticals Names Ogilvy Health as PR and Marketing Agency of Record to Drive Strategic Brand Repositioning and Enhance Market VisibilityNew York, NY and Woburn, MA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals names Ogilvy Health as public relations and marketing agency of record. Ogilvy Health's mandate will focus on reimagining Azurity's brand story centered on patient commitment and pioneering growth. The agency will also enhance Azurity's external visibility – both online and offline – and oversee the development of a new website to deliver dynamic content to all stakeholders, ensuring measurable impact across every channel.
Azurity Pharmaceuticals Announces FDA Approval of JAVADIN™ (clonidine hydrochloride) Oral SolutionFirst and Only FDA-Approved, Ready-to-Use Clonidine Oral Solution for Hypertension Control in Adult Patients
Azurity Pharmaceuticals Announces the FDA Approval of Ferabright<sup>TM</sup> (ferumoxytol injection), the First and Only Iron-Based Contrast Agent Indicated for Magnetic Resonance Imaging of the BrainWoburn, MA, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Azurity Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FerabrightTM (ferumoxytol injection), the first and only iron-based contrast agent indicated for magnetic resonance imaging (MRI) of the brain in adults with known or suspected malignant neoplasms in the brain to visualize lesions with a disrupted blood-brain barrier.1
